Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(57.1%)
Phase 2
3(42.9%)
7Total
Phase 1(4)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07524322Phase 1Recruiting

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Role: lead

NCT05304962Phase 1Recruiting

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Role: lead

NCT06277934Phase 2Completed

A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities

Role: lead

NCT06867718Phase 2Active Not Recruiting

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions

Role: lead

NCT06299124Phase 1Active Not Recruiting

A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

Role: lead

NCT05764915Phase 1Terminated

A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors

Role: lead

NCT05297045Phase 2Terminated

A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

Role: lead

All 7 trials loaded